Zevra Therapeutics, Inc. - Common Stock (ZVRA)
Frequently Asked Questions About Zevra Therapeutics, Inc. - Common Stock (ZVRA)
Does Zevra Therapeutics engage in partnerships or collaborations?
Yes, Zevra Therapeutics actively seeks partnerships and collaborations with other biotech companies, academic institutions, and healthcare organizations to enhance its research capabilities and expedite the development of its therapeutic candidates.
How can investors learn more about Zevra Therapeutics?
Investors can learn more about Zevra Therapeutics by visiting the company’s official website, where detailed information about its products, clinical trials, and corporate updates are provided. Additionally, the company releases quarterly financial reports and holds investor conferences to communicate its progress and plans.
How does Zevra Therapeutics address patient needs?
Zevra Therapeutics places a strong emphasis on addressing patient needs by actively soliciting input from patients, caregivers, and healthcare professionals. The company conducts surveys and forums to better understand the challenges faced by patients, ensuring that its therapies are relevant and effective.
How does Zevra Therapeutics assess the safety and efficacy of its therapies?
Zevra Therapeutics follows stringent regulatory guidelines to assess the safety and efficacy of its therapeutics. The company conducts preclinical studies followed by phased clinical trials, where it evaluates the drug's performance and gathers data to ensure it meets safety standards before seeking market approval.
How does Zevra Therapeutics utilize technology in its research?
Zevra Therapeutics utilizes advanced technologies in research and development, including genomics, proteomics, and bioinformatics. By leveraging these technologies, the company enhances its ability to identify potential therapeutic targets and streamline the drug discovery process.
Is Zevra Therapeutics publicly traded?
Yes, Zevra Therapeutics, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol ZVRA. The company’s public listing allows it to raise capital for further development of its therapeutics and expand its research initiatives.
What are the potential challenges facing Zevra Therapeutics?
Zevra Therapeutics faces several challenges typical of the biotech sector, including the high costs of research and development, the complexities of navigating regulatory approval processes, and the need to demonstrate the safety and efficacy of its therapeutic candidates in competitive markets.
What does Zevra Therapeutics, Inc. do?
Zevra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutics for patients suffering from rare diseases and critical conditions. The company's mission is to create breakthrough treatments that address unmet medical needs, particularly in the areas of central nervous system disorders and other orphan diseases.
What is the company's approach to corporate social responsibility?
Zevra Therapeutics believes in corporate social responsibility and is committed to giving back to the community. The company engages in initiatives focused on education, healthcare access, and supporting research into rare diseases, demonstrating its commitment to making a positive impact beyond business objectives.
What is the company's vision for the future?
Zevra Therapeutics aims to be a leader in the biotechnology industry by advancing therapeutics that improve the lives of patients with rare diseases. The company's vision includes expanding its pipeline with innovative treatments and fostering relationships with stakeholders in the healthcare sector to enhance patient access to new therapies.
What is the company’s approach to drug development?
Zevra Therapeutics adopts a patient-centric approach to drug development, focusing on understanding the unique challenges faced by patients with rare diseases. The company emphasizes rigorous scientific research and aims to collaborate with healthcare providers and patients to bring effective treatments to market.
What is the significance of orphan drug designation?
Orphan drug designation is significant as it provides certain regulatory advantages, such as tax credits, reduced fees, and market exclusivity for drugs developed to treat rare diseases. This designation encourages companies like Zevra Therapeutics to invest in the development of treatments that might otherwise be commercially unfeasible due to small patient populations.
What is Zevra Therapeutics’ flagship product?
One of Zevra Therapeutics' flagship products is its lead therapeutic candidate, which is currently undergoing clinical trials. This candidate is designed to address specific symptoms associated with rare diseases and has shown promise in early development stages.
What recent milestones has Zevra Therapeutics achieved?
Recently, Zevra Therapeutics has achieved significant milestones, including progressing multiple therapeutic candidates into clinical trials, receiving orphan drug designation from regulatory agencies, and announcing partnerships for further research initiatives. These accomplishments reflect the company's commitment to innovation.
What regulatory approvals has Zevra Therapeutics received?
Zevra Therapeutics has received various regulatory designations, including orphan drug designation and fast-track designation for certain therapeutic candidates. These approvals help expedite the development process and allow the company to work closely with regulatory bodies to bring safe and effective treatments to patients.
What types of diseases does Zevra Therapeutics target?
Zevra Therapeutics primarily targets rare diseases, particularly those affecting the central nervous system, including neurodegenerative diseases and genetic disorders. The company aims to provide novel treatments for patients facing significant challenges due to their conditions.
When was Zevra Therapeutics, Inc. founded?
Zevra Therapeutics, Inc. was founded in 2010, and since its inception, it has been dedicated to researching and developing therapeutic solutions for conditions that currently lack effective treatments.
Where is Zevra Therapeutics, Inc. located?
Zevra Therapeutics, Inc. is headquartered in San Diego, California. The strategic location allows the company to be part of a vibrant biotech hub, facilitating collaborations with research institutions and other biotechnology firms.
Who are the key executives at Zevra Therapeutics?
Zevra Therapeutics is led by a team of experienced professionals in the biotechnology sector, including a CEO, COO, and other senior executives who bring a wealth of knowledge in drug development, business strategy, and regulatory affairs. These leaders are committed to driving the company's mission forward.
What is the current price of Zevra Therapeutics, Inc. - Common Stock?
The current price of Zevra Therapeutics, Inc. - Common Stock is 6.950
When was Zevra Therapeutics, Inc. - Common Stock last traded?
The last trade of Zevra Therapeutics, Inc. - Common Stock was at 2:54 pm EDT on April 4th, 2025